2025 India Ai-Based Clinical Trials Revenue Opportunities Report
Description
The 2025 India Ai-Based Clinical Trials Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in India include IQVIA, Syneos Health, PPD (now part of Thermo Fisher Scientific), and Parexel. IQVIA leads with its advanced analytics and technology solutions, driving innovations in patient recruitment, adaptive trials, and data integration essential for precision outcomes in oncology and other therapeutic areas. Syneos is noted for AI-powered trial design and patient-centric studies, leveraging AI for recruitment and forecasting. PPD enhances trial capabilities in biomarker research and genomics, supporting early-phase to post-market studies. Parexel excels in personalized medicine trials, regulatory affairs, and hybrid trial models, fostering efficient global submissions and data management in India.
These companies are complemented by emerging Indian AI-biotech firms such as Qure.ai, which revolutionizes diagnostics with AI-driven imaging, and IndiGene Bio, specializing in AI genomics for rare diseases and cancer mutations. The Indian government's strong policy support and rich genomic datasets empower these companies to innovate in clinical trial design using AI. The AI-based clinical trials market in India is growing rapidly due to regulatory reforms and increasing technological adoption by pharmaceutical and healthcare players, further attracting global collaborations that reduce trial costs and timelines while improving accuracy and outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in India include IQVIA, Syneos Health, PPD (now part of Thermo Fisher Scientific), and Parexel. IQVIA leads with its advanced analytics and technology solutions, driving innovations in patient recruitment, adaptive trials, and data integration essential for precision outcomes in oncology and other therapeutic areas. Syneos is noted for AI-powered trial design and patient-centric studies, leveraging AI for recruitment and forecasting. PPD enhances trial capabilities in biomarker research and genomics, supporting early-phase to post-market studies. Parexel excels in personalized medicine trials, regulatory affairs, and hybrid trial models, fostering efficient global submissions and data management in India.
These companies are complemented by emerging Indian AI-biotech firms such as Qure.ai, which revolutionizes diagnostics with AI-driven imaging, and IndiGene Bio, specializing in AI genomics for rare diseases and cancer mutations. The Indian government's strong policy support and rich genomic datasets empower these companies to innovate in clinical trial design using AI. The AI-based clinical trials market in India is growing rapidly due to regulatory reforms and increasing technological adoption by pharmaceutical and healthcare players, further attracting global collaborations that reduce trial costs and timelines while improving accuracy and outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
